Biologic safety in psoriasis: review of long-term safety data.
The development of targeted biologic agents has revolutionized the treatment of psoriasis. In this review, the authors focus on the published long-term (≥ one year) safety data for the use of tumor necrosis factor-α antagonists etanercept, infliximab, and adalimumab, as well as the IL-12/IL-23 antagonist ustekinumab, in adult patients with moderate-to-severe psoriasis. The efficacy of these currently available biologic therapies has been demonstrated in several studies, and their safety profiles are also reassuring.
The Icahn School of Medicine at Mount Sinai, Department of Dermatology, New York, New York.
Yasaman
Y
Mansouri
The Icahn School of Medicine at Mount Sinai, Department of Dermatology, New York, New York.
Gary
G
Goldenberg